PA8554701A1 - Uso de una combinacion de compuestos en un inhalador de polvo seco - Google Patents
Uso de una combinacion de compuestos en un inhalador de polvo secoInfo
- Publication number
- PA8554701A1 PA8554701A1 PA20028554701A PA8554701A PA8554701A1 PA 8554701 A1 PA8554701 A1 PA 8554701A1 PA 20028554701 A PA20028554701 A PA 20028554701A PA 8554701 A PA8554701 A PA 8554701A PA 8554701 A1 PA8554701 A1 PA 8554701A1
- Authority
- PA
- Panama
- Prior art keywords
- formula
- dry powder
- powder inhaler
- treatment
- compound combination
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 229940112141 dry powder inhaler Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- 239000002131 composite material Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000007787 solid Substances 0.000 abstract 2
- 230000007774 longterm Effects 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 238000005259 measurement Methods 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M13/00—Insufflators for therapeutic or disinfectant purposes, i.e. devices for blowing a gas, powder or vapour into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE A UNA FORMULACION DE INHALACION QUE COMPRENDE UNA COMBINACION DE UN COMPUESTO SELECCIONADO ENTRE UNA CLASE PARTICULAR DE 5,6-DEHIDRO-9H-PIRAZOLO [3,4-C]-1,2,4-TRIAZOLO[4,4-A] PIRIDINAS DE FORMULA (I) Y UNA SAL TIOTROPIO O SOLVATO DE CUALQUIERA DE ELLOS, QUE ES CAPAZ DE LIBERAR EL COMPUESTO DE FORMULA (I) EN FORMA DE PARTICULAS SOLIDAS FINAS EN UN PULMON. LA INVENCION TAMBIEN INCLUYE EL USO DE TAL FORMULACION EN EL TRATAMIENTO DE CIERTAS ENFERMEDADES TALES COMO LAS ENFERMEDADES RESPIRATORIAS. POR MEDIO DEL USO DE TALES FORMULACIONES ES POSIBLE ELIMINAR LA RESPUESTA DE TOS INDESEADA ASOCIADA CON EL USO DE LOS COMPUESTOS DE FORMULA (I) EN INHALADORES DE DOSIS MEDIDA DE SOLUCION, PUDIENDO AFECTAR NEGATIVAMENTE TAL RESPUESTAS A LA ADMINISTRACION DE UNA DOSIS TERAPEUTICAMENTE EFICAZ Y, A LARGO PLAZO, IMPEDIR EL CUMPLIMIENTO DEL TRATAMENTO POR PARTE DEL PACIENTE.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0122031.8A GB0122031D0 (en) | 2001-09-12 | 2001-09-12 | Use of pde4 inhibitors in a dry powder inhaler |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PA8554701A1 true PA8554701A1 (es) | 2003-09-17 |
Family
ID=9921954
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PA20028554601A PA8554601A1 (es) | 2001-09-12 | 2002-09-12 | Uso de compuestos en un inhalador de polvo seco |
| PA20028554701A PA8554701A1 (es) | 2001-09-12 | 2002-09-12 | Uso de una combinacion de compuestos en un inhalador de polvo seco |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PA20028554601A PA8554601A1 (es) | 2001-09-12 | 2002-09-12 | Uso de compuestos en un inhalador de polvo seco |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US20030064031A1 (es) |
| EP (1) | EP1427414A1 (es) |
| JP (1) | JP2005505560A (es) |
| KR (1) | KR20040036940A (es) |
| CN (1) | CN1553801A (es) |
| AP (2) | AP2002002623A0 (es) |
| AR (2) | AR036474A1 (es) |
| BG (1) | BG108569A (es) |
| BR (1) | BR0212449A (es) |
| CA (1) | CA2457717A1 (es) |
| CZ (1) | CZ2004310A3 (es) |
| EA (1) | EA006742B1 (es) |
| EC (1) | ECSP045018A (es) |
| EE (1) | EE200400078A (es) |
| GB (1) | GB0122031D0 (es) |
| HN (2) | HN2002000253A (es) |
| HR (1) | HRP20040162A2 (es) |
| HU (1) | HUP0401890A3 (es) |
| IL (1) | IL160380A0 (es) |
| IS (1) | IS7151A (es) |
| MA (1) | MA27062A1 (es) |
| MX (1) | MXPA04002354A (es) |
| NO (1) | NO20041011L (es) |
| NZ (1) | NZ530929A (es) |
| OA (1) | OA12660A (es) |
| PA (2) | PA8554601A1 (es) |
| PE (2) | PE20030509A1 (es) |
| PL (1) | PL368736A1 (es) |
| SK (1) | SK1272004A3 (es) |
| SV (2) | SV2004001227A (es) |
| TN (1) | TNSN04040A1 (es) |
| TW (1) | TW200602054A (es) |
| WO (2) | WO2003022275A1 (es) |
| ZA (1) | ZA200401002B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040176391A1 (en) * | 2002-12-31 | 2004-09-09 | Nektar Therapeutics | Aerosolizable pharmaceutical formulation for fungal infection therapy |
| US7931022B2 (en) | 2001-10-19 | 2011-04-26 | Respirks, Inc. | Method and apparatus for dispensing inhalator medicament |
| GB0315889D0 (en) | 2003-07-08 | 2003-08-13 | Aventis Pharma Ltd | Stable pharmaceutical products |
| US20060009435A1 (en) * | 2004-06-23 | 2006-01-12 | Joseph Kaspi | Synthesis and powder preparation of fluticasone propionate |
| WO2007036029A1 (en) * | 2005-09-28 | 2007-04-05 | Merck Frosst Canada Ltd. | Aerosol powder formulation comprising sieved lactose |
| GB0801876D0 (en) * | 2008-02-01 | 2008-03-12 | Vectura Group Plc | Suspension formulations |
| US8834931B2 (en) | 2009-12-25 | 2014-09-16 | Mahmut Bilgic | Dry powder formulation containing tiotropium for inhalation |
| TR200909788A2 (tr) * | 2009-12-25 | 2011-07-21 | Bi̇lgi̇ç Mahmut | Tiotropyum içeren inhalasyona uygun kuru toz formülasyonu |
| AP2015008663A0 (en) | 2013-02-19 | 2015-08-31 | Pfizer | Azabenzimidazole compounds as inhibitors of PDE4 isozymes for the treatment of cns and other disorders |
| KR20150076005A (ko) | 2013-12-26 | 2015-07-06 | 삼성디스플레이 주식회사 | 액정 표시 장치 |
| JP6713982B2 (ja) | 2014-07-24 | 2020-06-24 | ファイザー・インク | ピラゾロピリミジン化合物 |
| CU20170007A7 (es) | 2014-08-06 | 2017-06-05 | Pfizer | Compuestos de imidazopiridazina |
| CN111249260B (zh) * | 2014-09-15 | 2023-01-10 | 维罗纳制药公司 | 包含rpl554的液体吸入制剂 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6004974A (en) * | 1995-06-06 | 1999-12-21 | Pfizer Inc | Tricyclic 5,6-dihydro-9h-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridines |
| US5985309A (en) * | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| DE19835346A1 (de) * | 1998-08-05 | 2000-02-10 | Boehringer Ingelheim Pharma | Zweiteilige Kapsel zur Aufnahme von pharmazeutischen Zubereitungen für Pulverinhalatoren |
-
2001
- 2001-09-12 GB GBGB0122031.8A patent/GB0122031D0/en not_active Ceased
-
2002
- 2002-09-02 OA OA1200400071A patent/OA12660A/en unknown
- 2002-09-02 WO PCT/IB2002/003599 patent/WO2003022275A1/en not_active Application Discontinuation
- 2002-09-02 IL IL16038002A patent/IL160380A0/xx unknown
- 2002-09-02 JP JP2003526404A patent/JP2005505560A/ja not_active Withdrawn
- 2002-09-02 NZ NZ530929A patent/NZ530929A/en unknown
- 2002-09-02 WO PCT/IB2002/003598 patent/WO2003022279A1/en not_active Application Discontinuation
- 2002-09-02 EA EA200400301A patent/EA006742B1/ru not_active IP Right Cessation
- 2002-09-02 BR BR0212449-1A patent/BR0212449A/pt not_active IP Right Cessation
- 2002-09-02 CA CA002457717A patent/CA2457717A1/en not_active Abandoned
- 2002-09-02 EP EP02767763A patent/EP1427414A1/en not_active Withdrawn
- 2002-09-02 PL PL02368736A patent/PL368736A1/xx not_active Application Discontinuation
- 2002-09-02 HU HU0401890A patent/HUP0401890A3/hu unknown
- 2002-09-02 MX MXPA04002354A patent/MXPA04002354A/es not_active Application Discontinuation
- 2002-09-02 CZ CZ2004310A patent/CZ2004310A3/cs unknown
- 2002-09-02 SK SK127-2004A patent/SK1272004A3/sk not_active Application Discontinuation
- 2002-09-02 KR KR10-2004-7003619A patent/KR20040036940A/ko active IP Right Grant
- 2002-09-02 EE EEP200400078A patent/EE200400078A/xx unknown
- 2002-09-02 CN CNA028178874A patent/CN1553801A/zh active Pending
- 2002-09-05 US US10/236,551 patent/US20030064031A1/en active Pending
- 2002-09-05 US US10/236,228 patent/US20030064034A1/en not_active Abandoned
- 2002-09-10 AR ARP020103427A patent/AR036474A1/es unknown
- 2002-09-10 AR ARP020103426A patent/AR036473A1/es unknown
- 2002-09-10 PE PE2002000893A patent/PE20030509A1/es not_active Application Discontinuation
- 2002-09-10 PE PE2002000894A patent/PE20030443A1/es not_active Application Discontinuation
- 2002-09-11 TW TW094130352A patent/TW200602054A/zh unknown
- 2002-09-11 HN HN2002000253A patent/HN2002000253A/es unknown
- 2002-09-12 PA PA20028554601A patent/PA8554601A1/es unknown
- 2002-09-12 AP APAP/P/2002/002623A patent/AP2002002623A0/en unknown
- 2002-09-12 SV SV2002001227A patent/SV2004001227A/es not_active Application Discontinuation
- 2002-09-12 PA PA20028554701A patent/PA8554701A1/es unknown
- 2002-09-12 AP APAP/P/2002/002624A patent/AP2002002624A0/en unknown
- 2002-09-12 SV SV2002001226A patent/SV2004001226A/es not_active Application Discontinuation
- 2002-10-11 HN HN2002000254A patent/HN2002000254A/es unknown
-
2004
- 2004-02-06 ZA ZA200401002A patent/ZA200401002B/en unknown
- 2004-02-09 BG BG108569A patent/BG108569A/bg unknown
- 2004-02-13 IS IS7151A patent/IS7151A/is unknown
- 2004-02-19 HR HR20040162A patent/HRP20040162A2/xx not_active Application Discontinuation
- 2004-02-26 MA MA27550A patent/MA27062A1/fr unknown
- 2004-03-10 NO NO20041011A patent/NO20041011L/no not_active Application Discontinuation
- 2004-03-10 TN TNP2004000040A patent/TNSN04040A1/fr unknown
- 2004-03-12 EC EC2004005018A patent/ECSP045018A/es unknown
-
2005
- 2005-06-13 US US11/152,741 patent/US20050232871A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PA8554701A1 (es) | Uso de una combinacion de compuestos en un inhalador de polvo seco | |
| ITMI20051999A1 (it) | Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita' | |
| UY30265A1 (es) | Inhalador | |
| AR018161A1 (es) | Dispositivo para administrar un agente activo a los pulmones de un paciente humano | |
| CO5611174A2 (es) | Inhalador de polvo seco | |
| HN2008000964A (es) | Enmascaramiento del sabor de polvos | |
| AR052759A1 (es) | Dispositivo inhalador de medicamentos | |
| WO2007064658A3 (en) | Safe and effective methods of administering therapeutic agents | |
| UY34838A (es) | Nueva forma de dosificación y formulación | |
| WO2005041921A3 (en) | Dry powder compositions for inhalation therapy comprising calcium stearate, medical devices therefor | |
| BR112015027247A2 (pt) | composições farmacêuticas inaláveis e dispositivos inaladores contendo as mesmas | |
| ES2656913T3 (es) | Endrogenina A y agentes antineoplásicos para el tratamiento de tumores quimiosensibles o quimiorresistentes | |
| ES2542177T3 (es) | Uso de osmolitos obtenidos de bacterias extremófilas para la fabricación de medicamentos inhalables para la prevención y el tratamiento de enfermedades pulmonares y cardiovasculares, así como un dispositivo de inhalación que contiene osmolitos como componentes activos | |
| MX2021011491A (es) | Polvos secos inhalables. | |
| DOP2002000454A (es) | Uso de una combinacion de compuesto en un inhalador de polvo seco. | |
| CO6190610A2 (es) | Nueva utilizacion terapeutica para el tratamiento de las leucemias | |
| ES2182504T3 (es) | Bifenilsulfonilcianamidas, procedimiento para su preparacion y su utilizacion como medicamento. | |
| DE60336089D1 (de) | Aerosolformulierung umfassend Levalbuterol L-Tartratsalz | |
| UY27442A1 (es) | Uso de una combinación de compuestos en un inhalador de polvo seco.. | |
| UY27441A1 (es) | Uso de compuestos en un inhalador de polvo seco. | |
| CR7270A (es) | Uso de compuestos en un inhalador de polvo seco | |
| UY31541A1 (es) | 1(2)h-tetrazol-5-il-fenil-oxazolidinona s como agentes antibacterianos | |
| BR112022011096A2 (pt) | Dispositivos inaladores, formulações de medicamentos usados com os mesmos e métodos de fabricação | |
| TH58319B (th) | การใช้การรวมกันของสารประกอบในเครื่องใส่ยาดมชนิดผงแห้ง | |
| ECSP067003A (es) | Formulaciones en polvo para la inhalación, las cuales contienen beta-agonistas enantioméricamente puros |